Background: Recent clinical trials have shown that adjunctive glucocorticoids is associated
with inhibiting excessive inflammatory response and modulating cytokines release offering …

Corticosteroids for community-acquired pneumonia: a critical view of the evidence | European
Respiratory Society Skip to main content Main menu Home Current issue ERJ Early View Past …

Objective: To assess the evidence for adjunctive corticosteroids for severe community-
acquired pneumonia (CAP). Data Sources: MEDLINE (1966–February 2007) and EMBASE …

Background Clinical trials yielded conflicting data about the benefit of adding systemic
corticosteroids for treatment of community-acquired pneumonia. We assessed whether short …

Importance In patients with severe community-acquired pneumonia, treatment failure is
associated with excessive inflammatory response and worse outcomes. Corticosteroids may …

The relationship between low-dose corticosteroid use and mortality in patients with severe
community-acquired pneumonia (CAP) remains unclear. 6925 patients with severe CAP …

The use of corticosteroids in the management of pneumonia is still a controversial issue. The
physicians in daily clinical practice often use corticosteroids in patients with pneumonia for …

Importance Community-acquired pneumonia remains a leading cause of hospitalization,
mortality, and health care costs worldwide. Randomized clinical trials support the use of …

BACKGROUND Community‐acquired pneumonia (CAP) is a leading cause of morbidity and
mortality among adults. Although steroids appear to be beneficial in animal models of CAP …

Dear Editor, In a preliminary randomized trial of patients with severe communityacquired
pneumonia (CAP), we reported that glucocorticoid treatment was associated with …